DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
NOVA-22007 is an investigational drug.
There have been 24 clinical trials for NOVA-22007. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2012.
The most common disease conditions in clinical trials are Diabetes Mellitus, Diabetes Mellitus, Type 2, and Insulin Resistance. The leading clinical trial sponsors are Canadian Institutes of Health Research (CIHR), Nova Scotia Health Authority, and Canadian Network for Observational Drug Effect Studies, CNODES.
There are two US patents protecting this investigational drug and forty-six international patents.
Recent Clinical Trials for NOVA-22007
|Trial of Maintenance With Niraparib- Uterine Serous Carcinoma||Tesaro, Inc.||Phase 2|
|Trial of Maintenance With Niraparib- Uterine Serous Carcinoma||Northwell Health||Phase 2|
|Lisdexamfetamine for Adults With Bulimia Nervosa||Nova Scotia Health Authority||Phase 2|
Top disease conditions for NOVA-22007
Top clinical trial sponsors for NOVA-22007
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|NOVA-22007||Start Trial||Methods for determining risk of chronic lung allograft dysfunction (CLAD) and subtypes thereof||University Health Network (Toronto, CA)||Start Trial|
|NOVA-22007||Start Trial||Targeted poorly water-soluble drug delivery system, method of preparing the same, and pharmaceutical composition including the same||SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (Seoul, KR)||Start Trial|
|NOVA-22007||Start Trial||Low, immune enhancing, dose mtor inhibitors and uses thereof||Novartis AG (Basel, CH)||Start Trial|
|NOVA-22007||Start Trial||Substituted indole Mcl-1 inhibitors||Vanderbilt University (Nashville, TN)||Start Trial|
|NOVA-22007||Start Trial||Salts of an epidermal growth factor receptor kinase inhibitor||Celgene CAR LLC (Pembroke, BM)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|NOVA-22007||European Patent Office||2959017||2033-02-20||Start Trial|
|NOVA-22007||World Intellectual Property Organization (WIPO)||2014127463||2033-02-20||Start Trial|
|NOVA-22007||European Patent Office||2896401||2032-09-12||Start Trial|
|NOVA-22007||South Korea||101493930||2032-09-12||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|